What is VITA 34 AG?
FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally.
VTIAF · Verdict
Moderate reward · elevated risk
VTIAF stands out on growth and volatility, but watch the profitability signal.
Based on 88% data coverage
VTIAF · Verdict
Rev +42.5% CAGR · earnings +49.0%
Above average
-15% net margin · -58% ROE
Current ratio 0.73
7% free-cash-flow margin
Below average
Model-based scoring. For information only — not financial advice.
FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 139.84M.
The scoring profile indicates limited reward potential at this time, with growth and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.